PRELUDE THERAPEUTICS INC (PRLD) Shareholder Equity
- 2026-06-30: Additional Paid in Capital, Common StockUSD $841.32M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-227.00K; Retained Earnings (Accumulated Deficit)USD $-707.37M; Stockholders' Equity Attributable to ParentUSD $133.73M.
- 2026-03-31: Additional Paid in Capital, Common StockUSD $753.66M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-41.00K; Retained Earnings (Accumulated Deficit)USD $-693.45M; Stockholders' Equity Attributable to ParentUSD $60.18M.
- 2025-12-31: Additional Paid in Capital, Common StockUSD $751.68M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $8.00K; Retained Earnings (Accumulated Deficit)USD $-683.06M; Stockholders' Equity Attributable to ParentUSD $68.64M.
- 2025-09-30: Additional Paid in Capital, Common StockUSD $725.13M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.00K; Retained Earnings (Accumulated Deficit)USD $-666.60M; Stockholders' Equity Attributable to ParentUSD $58.53M.
PRELUDE THERAPEUTICS INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD |
|---|---|---|---|---|
| 2026-06-30 | $841.32M | $-227.00K | $-707.37M | $133.73M |
| 2026-03-31 | $753.66M | $-41.00K | $-693.45M | $60.18M |
| 2025-12-31 | $751.68M | $8.00K | $-683.06M | $68.64M |
| 2025-09-30 | $725.13M | $2.00K | $-666.60M | $58.53M |
| 2025-06-30 | $722.71M | $-1.00K | $-646.88M | $75.84M |
| 2025-03-31 | $718.81M | $12.00K | $-615.65M | $103.18M |
| 2024-12-31 | $714.98M | $35.00K | $-583.56M | $131.46M |
| 2024-09-30 | $711.09M | $167.00K | $-554.83M | $156.43M |
| 2024-06-30 | $705.12M | $-290.00K | $-522.56M | $182.28M |
| 2024-03-31 | $698.78M | $-235.00K | $-487.82M | $210.73M |
| 2023-12-31 | $693.25M | $223.00K | $-456.39M | $237.09M |
| 2023-09-30 | $662.17M | $-605.00K | $-423.31M | $238.26M |
| 2023-06-30 | $655.47M | $-711.00K | $-392.71M | $262.06M |
| 2023-03-31 | $537.97M | $-398.00K | $-362.28M | $175.30M |
| 2022-12-31 | $531.68M | $-1.69M | $-334.56M | $195.44M |
| 2022-09-30 | $525.68M | $-2.36M | $-305.92M | $217.41M |
| 2022-06-30 | $519.09M | $-2.29M | $-275.96M | $240.84M |
| 2022-03-31 | $512.71M | $-2.31M | $-248.59M | $261.81M |
| 2021-12-31 | $505.72M | $-711.00K | $-219.12M | $285.90M |
| 2021-09-30 | $497.69M | $-176.00K | $-186.28M | $311.24M |
| 2021-06-30 | $489.95M | (m) | $-155.59M | $334.36M |
| 2021-03-31 | $485.29M | (m) | $-128.73M | $356.57M |
| 2020-12-31 | $319.61M | (m) | $-107.43M | $212.18M |
| 2020-09-30 | $316.48M | (m) | $-88.18M | $228.31M |
| 2020-06-30 | (m) | (m) | (m) | $-69.31M |
| 2020-03-31 | (m) | (m) | (m) | $-58.56M |
| 2019-12-31 | $1.08M | (m) | $-50.50M | $-49.41M |
| 2019-09-30 | (m) | (m) | (m) | $-39.70M |
| 2019-06-30 | (m) | (m) | (m) | $-33.26M |
| 2019-03-31 | (m) | (m) | (m) | $-27.85M |
| 2018-12-31 | (m) | (m) | (m) | $-22.69M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |